INDOlink
Glenmark Gets Tentative USFDA Nod for Migraine Tablets Email this page
Print this page
Bangalore: Glenmark Pharmaceuticals said it has received tentative approval from the U.S. health regulator for its generic Rizatriptan Benzoate tablets used for treating migraine attacks.
The company’s U.S. arm Glenmark Generics U.S.A. has received tentative approval for Rizatriptan Benzoate tablets from the U.S. Food and Drug Administration (USFDA), Glenmark Pharmaceuticals said in a statement.

These migraine tablets are the generic version of the drug major Merck’s Maxalt tablets, it added. Quoting IMS Health data, the company, Glenmark Pharmaceuticals, said Rizatriptan Benzoate immediate release tablets achieved sales of $315 million for the 12 month period that ended in June 2012.

Current portfolio of the company consists of 81 products authorised for distribution in the U.S. market and 41 abbreviated new drug applications (ANDAs) pending approval with the USFDA. Shares of Glenmark Pharmaceuticals were trading at 416 per scrip on Bombay Stock Exchange in the afternoon trade, up 0.96 percent from its previous close.

Home About Us Jobs Comments Contact Us Advertise Terms of Service Privacy Policy
Copyright © 1995-2013 INDOlink.com, Inc. All Rights Reserved.
INDOlink, Planet Bollywood, "Best of Both Worlds", "Linking Indians Worldwide" are trademarks of INDOlink.com, Inc.